The Guide contains practical advice on implementing HIV and hepatitis C programs with people who inject drugs and can be used by policy makers, practitioners and advocates to promote effective policy and practice.
EU Member States could learn from past experiences in legalizing cannabis for medical and non-medical purposes, and decide if they want to maintain their current cannabis supply policies or try evidence-based alternatives.
This paper gives an overview of some recent developments in the tools most commonly used to manage national drug policies: strategies, coordination mechanisms and evaluations.
This paper explores areas for future development outlining the key implications for those engaged in planning or delivering health and social care responses to illicit drug use, specifically in relation to ageing drug users.
In this advocacy note, IDPC offers some analysis and key recommendations on CBD and tramadol to inform the ECDD’s meeting set to take place in November 2017.
This IDPC progress report provides an overview of our activities between 2016 and 2017, including our continuing efforts to build capacity for drug policy advocacy and the numerous publications and resources produced during this period.
This EMCDDA report presents a brief overview of recent evidence for the most effective approaches in the fields of drug use prevention, drug use treatment and harm reduction.
The EMCDDA sheds light on the specific challenges affecting women who use drugs, gaps in knowledge and policy recommendations for policies and practices to be gender mainstreamed.
UNAIDS and UNFPA have consulted with a broad range of stakeholders to produce a document that identifies key avenues towards the attainment of the 2030 goals.
